# Open Label Trial for Post-Menopausal Women With Newly Diagnosed Operable Breast Cancer

> **NCT00161291** · PHASE2 · COMPLETED · sponsor: **University of Alabama at Birmingham** · enrollment: 28 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Letrozole in combination with Bevacizumab

## Key facts

- **NCT ID:** NCT00161291
- **Lead sponsor:** University of Alabama at Birmingham
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-06
- **Primary completion:** 2006-11
- **Final completion:** 2006-11
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2011-01-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00161291

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00161291, "Open Label Trial for Post-Menopausal Women With Newly Diagnosed Operable Breast Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00161291. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*